CRISPR technology is a group of molecular biology methods that use components derived from a natural microbial defence system to make targeted changes to genetic material. CRISPR originally refers to clustered regularly interspaced short palindromic repeats, distinctive DNA sequences found in many bacteria and archaea, where they form part of an adaptive immune system that helps recognise and respond to genetic material from viruses and other mobile genetic elements.
Researchers adapted this biological mechanism into a programmable gene-editing platform by combining a guide RNA that identifies a chosen genetic sequence with a CRISPR-associated protein, commonly a nuclease such as Cas9, that can cut DNA at or near the targeted location. The resulting DNA break can be repaired by the cell, and the repair process can be exploited to disrupt genes, introduce specific sequence changes or make other controlled genetic modifications. CRISPR is therefore not a single product or procedure but a broad family of technologies whose capabilities depend on the CRISPR system, guide design, target organism, delivery method and editing objective.
The best-known CRISPR system is CRISPR-Cas9. In a typical Cas9-based design, a guide RNA contains a sequence complementary to the intended DNA target, while Cas9 provides the enzymatic activity that cuts the DNA. Cas9 generally requires a nearby protospacer adjacent motif, or PAM, whose sequence depends on the particular Cas protein being used. For the commonly used Streptococcus pyogenes Cas9 system, the canonical PAM is NGG.
The guide RNA directs Cas9 through base pairing with the target DNA, and Cas9 then creates a double-strand break at the selected site. Cellular DNA-repair pathways subsequently determine much of the final outcome. Non-homologous end joining can introduce small insertions or deletions that disrupt a coding sequence, whereas homology-directed repair can, under appropriate experimental conditions, use a supplied DNA template to make a more precise alteration. The technology's programmability distinguishes CRISPR from older gene-editing methods that often required more laborious engineering of a new DNA-binding protein for each target.
CRISPR has expanded substantially beyond conventional Cas9 cutting. Other CRISPR-associated proteins include Cas12 systems, which have different target-recognition and cleavage characteristics, and Cas13 systems, which target RNA rather than DNA. Catalytically inactive Cas proteins can be converted into programmable targeting platforms by disabling their cutting activity while retaining their ability to bind selected nucleic-acid sequences.
These systems can be coupled to transcriptional activators or repressors to alter gene expression without changing the DNA sequence itself, a strategy commonly described as CRISPR activation or CRISPR interference. Base editors combine targeted DNA recognition with enzymes capable of converting particular bases without creating a conventional double-strand break, while prime editors use a modified CRISPR-associated protein and a specialised guide to support a broader range of sequence changes. These variants demonstrate that “CRISPR” encompasses programmable molecular targeting, editing and regulation rather than merely the Cas9 double-strand-break technique.
CRISPR's applications extend across basic research, medicine, biotechnology, agriculture and diagnostics. In research, scientists can disable genes to investigate their functions, modify regulatory regions, create cellular or animal models of disease, screen large numbers of genes and study genetic interactions. In medicine, gene editing is being investigated or used in certain contexts to modify human cells for therapeutic purposes, including approaches involving blood disorders and cancer.
Ex vivo editing removes cells from a patient, modifies them in a controlled laboratory environment and returns them to the body, whereas in vivo approaches attempt to deliver editing components directly into tissues. In agriculture, CRISPR can be used to modify crop traits such as disease resistance, nutritional composition, maturation characteristics or tolerance to environmental stresses. In diagnostics, some CRISPR systems can be engineered to recognise specific nucleic-acid sequences and generate detectable signals, creating approaches for identifying pathogens or genetic sequences.
Delivery is one of the most important practical constraints on CRISPR technology. An editing system must reach the appropriate cells and expose them to the relevant molecular components at suitable concentrations and times. Experimental delivery methods include electroporation, lipid nanoparticles, viral vectors and direct introduction of purified proteins or RNA, with the appropriate method depending on the target tissue and organism.
In human therapeutics, delivery is particularly challenging because different organs and cell types have different biological barriers, immune characteristics and accessibility. Editing efficiency also varies among cell types and target sequences. Researchers must consider whether editing occurs in enough of the intended cells, whether the desired modification is produced, whether unwanted modifications occur and whether the editing components persist longer than necessary. These practical issues mean that demonstrating that a DNA sequence can theoretically be edited is very different from demonstrating that a CRISPR-based intervention is safe, effective and clinically useful.
CRISPR technology has important limitations and risks. Guide sequences can sometimes recognise genomic regions that resemble the intended target, producing unintended edits known as off-target effects. Even correctly targeted editing can produce a mixture of outcomes because DNA repair is not always predictable. Large deletions, rearrangements or other genomic changes can occur in some circumstances, depending on the editing system and cellular context. Delivery can also cause toxicity or immune responses, and editing efficiency can vary considerably.
In therapeutic applications, researchers therefore assess factors such as specificity, on-target activity, unintended genomic changes, delivery, durability, immune responses and long-term consequences. Germline editing, which would introduce changes potentially transmissible to future generations, raises additional scientific, ethical and regulatory issues compared with somatic editing, which affects an individual's non-reproductive cells. The existence of a technically feasible editing method does not by itself establish that a particular application is medically, ethically or legally appropriate.
The history of CRISPR combines discoveries in microbial genetics with developments in molecular biology and genome engineering. Repeated DNA sequences with unusual structures were reported in microorganisms before their biological function was understood. Subsequent research established that CRISPR loci and associated proteins participate in microbial adaptive immunity, with genetic material from previous encounters contributing to sequence-specific defence. The demonstration that CRISPR-Cas systems could be programmed for targeted genome modification transformed them into broadly accessible research tools.
The Cas9 system became particularly influential because its targeting mechanism could be redirected by changing the guide RNA rather than redesigning the protein itself. Later research produced alternative nucleases, base editors, prime editors, transcriptional regulators and RNA-targeting systems. The resulting field has evolved rapidly from a microbial defence mechanism into a general platform for programmable manipulation and detection of nucleic acids.
A common misconception is that CRISPR can simply “rewrite any gene” with perfect precision. In reality, target selection is constrained by the recognition requirements of the chosen CRISPR system, cellular biology, delivery and DNA-repair processes, and different editing objectives require different molecular strategies. CRISPR also differs from conventional genetic modification as a broad category: genetic modification can include many techniques for introducing or altering genetic material, whereas CRISPR describes a particular family of programmable molecular systems.
Gene editing similarly is broader than CRISPR because other editing technologies exist. The major significance of CRISPR is its combination of programmability, relatively straightforward guide redesign, scalability and a growing range of molecular functions. Its current scientific importance therefore comes not simply from cutting DNA, but from the broader ability to direct molecular activity towards selected nucleic-acid sequences.
